EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Immunoglobulin Light Chain Amyloidosis: 2026 Update on Diagnosis, Prognosis, and Treatment

Morie A Gertz iD

American Journal of Hematology · 2026-05 · 101 (5) · 1056-1069

DOI: 10.1002/ajh.70246 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Hematology, online erschienen am 22.02.2026. Verfasst von Morie A Gertz. Beteiligte Einrichtung: Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Immunoglobulin Light-chain Amyloidosis. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 119 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Disease Overview AL amyloidosis is a clonal plasma cell disorder in which fragments of immunoglobulin light or heavy chain are deposited in tissues. Clinical features depend on organs involved but can include HFpEF, nephrotic syndrome, hepatic dysfunction, peripheral/autonomic neuropathy, and “atypical smoldering multiple myeloma or MGUS.” Diagnosis Tissue biopsy stained with Congo red demonstrating amyloid deposits with apple‐green birefringence is required. Organ biopsy is not required in 85% of patients. Verification that amyloid is composed of immunoglobulin light chains is mandatory. Prognosis N‐terminal pro–brain natriuretic peptide (NT‐proBNP or BNP), serum troponin T (or I), and difference between involved and uninvolved immunoglobulin free light chain values are used to classify patients into four stages; 5 year survivals are 82%, 62%, 34%, and 20% respectively. Therapy All patients with a systemic amyloid syndrome require therapy to prevent deposition of amyloid in other organs and prevent progressive organ failure. Current first line therapy with the best outcome is daratumumab, bortezomib, cyclophosphamide, and dexamethasone. The goal of therapy is a ≥ VGPR. In patients failing to achieve this depth of response, options for consolidation include pomalidomide, stem cell transplantation, and venetoclax. T‐cell redirecting therapies, both bispecific antibodies and car T, show high level activity and may soon become standard second‐line therapy. Future Challenges Delayed diagnosis remains a major obstacle to initiating effective therapy prior to the development of end‐stage organ failure. An antibody to deplete deposited κ fibrils has reported benefit in patients with cardiomyopathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunoglobulin Light-chain AmyloidosisHumansPrognosisStem Cell TransplantationImmunoglobulin Light Chains

Stichwörter der Autor:innen

amyloidosisbispecific T cell engagersimmunoglobulin disordersinfiltrative cardiomyopathymass spectroscopystem cell transplant

Substanzen

Immunoglobulin Light Chains

Autor:innen und Institutionen

  • Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: Morie A Gertz

Zitieren

APA

Gertz, M. A. (2026). Immunoglobulin Light Chain Amyloidosis: 2026 Update on Diagnosis, Prognosis, and Treatment. American Journal of Hematology, 101(5), 1056-1069. https://doi.org/10.1002/ajh.70246

Vancouver

Gertz MA. Immunoglobulin Light Chain Amyloidosis: 2026 Update on Diagnosis, Prognosis, and Treatment. American Journal of Hematology. 2026;101(5):1056-1069. doi:10.1002/ajh.70246

BibTeX
@article{Gertz2026,
  author = {Gertz, Morie A},
  title = {Immunoglobulin Light Chain Amyloidosis: 2026 Update on Diagnosis, Prognosis, and Treatment},
  journal = {American Journal of Hematology},
  year = {2026},
  volume = {101},
  number = {5},
  pages = {1056--1069},
  doi = {10.1002/ajh.70246}
}
Kostenlos starten →